Celebrex Data Requested By FDA May Clarify Cancer Risk Reduction Potential
Executive Summary
FDA is requesting data from a Searle Phase III trial that could elucidate the cancer risk reduction that Celebrex provides for patients with familial adenomatous polyposis.
You may also be interested in...
Colorectal Chemopreventives Should Show 30% Adenoma Reduction – Cmte.
Chemopreventive agents should show at least a 30% reduction in the number of precancerous adenomas to be associated with a benefit in colorectal cancer risk reduction, FDA's Gastrointestinal Drugs Advisory Committee suggested March 19
Colorectal Chemopreventives Should Show 30% Adenoma Reduction – Cmte.
Chemopreventive agents should show at least a 30% reduction in the number of precancerous adenomas to be associated with a benefit in colorectal cancer risk reduction, FDA's Gastrointestinal Drugs Advisory Committee suggested March 19
Searle Oncology Given Boost By Pending P&U Merger, Antibody Deal
Searle will create a platform for new oncologics development through a research collaboration with Cambridge Antibody Technology.